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How does endothelial cell injury start? The role of endothelin in
systemic sclerosis
Abstract
A considerable amount of research time has been invested in studies aimed at elucidating pathogenic
processes in systemic sclerosis (SSc). Despite this, major challenges for biomedical science remain,
such as identification of the key factors that determine susceptibility to SSc, and elucidation of the
precise nature of the initiating event that causes endothelial cell injury and ultimately brings about the
biological cascade(s) that lead to the pathologic vascular changes. Involved factors are likely to include
genetic perturbations, environmental cues, tissue injury, infection and hypoxia/oxidative stress. As
important as determining the initiating events are the identification and characterization of key factors
that are functionally important in driving vascular disease progression, because these factors are
potential targets for therapeutic intervention. This article reviews the role of endothelin as an example of
a pleiotropic mediator with effects on various aspects of SSc pathogenesis, such as inflammation,
vasculopathy and tissue remodelling.
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Abstract
A considerable amount of research time has been invested in
studies aimed at elucidating pathogenic processes in systemic
sclerosis (SSc). Despite this, major challenges for biomedical
science remain, such as identification of the key factors that
determine susceptibility to SSc, and elucidation of the precise
nature of the initiating event that causes endothelial cell injury and
ultimately brings about the biological cascade(s) that lead to the
pathologic vascular changes. Involved factors are likely to include
genetic perturbations, environmental cues, tissue injury, infection
and hypoxia/oxidative stress. As important as determining the
initiating events are the identification and characterization of key
factors that are functionally important in driving vascular disease
progression, because these factors are potential targets for
therapeutic intervention. This article reviews the role of endothelin
as an example of a pleiotropic mediator with effects on various
aspects of SSc pathogenesis, such as inflammation, vasculopathy
and tissue remodelling.
Introduction
In order to understand the initiators of endothelial injury and
how the ensuing vascular dysfunction contributes to the
development of systemic sclerosis (SSc), it is necessary to
consider the normal biology of the endothelium and of the
myriad of biological molecules and biological functions under
its control, and to assess which specific processes are
dysregulated in disease. In SSc, the vasculopathy is one of
the earliest pathological events, characterized by endothelial
cell activation and altered vascular tone. These pathological
changes are accompanied by the presence of pro-
inflammatory cytokines and angiogenic regulatory factors, and
the loss of redox control, leading to oxidative stress and
hypoxia. This complex array of molecular interactions involves
a number of cell types including the endothelial cells and their
attendant perivascular supporting cells (pericytes and
vascular smooth muscle cells [vSMCs]), and inflammatory
cells, and they are profoundly influenced by the presence of
growth factors, cytokines, chemokines and potent vasoactive
factors. Together, this diverse range of factors is believed to
initiate and drive the vascular pathogenesis that leads to
severe vessel disease and occlusion. Here we focus on one
particularly attractive candidate, endothelin, and critically
examine the cellular and molecular activities mediated by
endothelin and its receptors that are intimately associated
with endothelial cell injury and vascular dysfunction in SSc.
The endothelium
The vascular endothelium is a complex, highly specialized and
metabolically active organ, which performs a number of
essential biological functions. The endothelium provides a
compatible interface to facilitate blood circulation, it
inherently inhibits excessive platelet aggregation and leuco-
cyte adhesion, and it produces a balance of vasoconstrictive
and vasodilatory molecules that coordinate vascular tone and
serve to inhibit extracellular matrix (ECM) deposition and
prevent smooth muscle cell proliferation. The endothelium
also serves as a multifunctional interface between blood and
all internal organs, selectively determining the movement of
macromolecules and governing the recruitment of circulating
cells from the blood into the extravascular tissues. The
prominent endocrine functions of the endothelium work to
regulate vascular tone, through the production of vaso-
constrictive (for instance, endothelin [ET]-1) and vasodilatory
(for example, nitric oxide and prostaglandins) molecules; to
maintain blood fluidity; to regulate platelet function; and to
control inflammation. Healthy functioning of the endothelium
is critical for remodelling of blood vessels, through angio-
genesis and vasculogenesis, during times of tissue growth
and repair. Thus, the endothelial cell phenotype must be
regulated, and this is achieved by environmental cues and
Review
How does endothelial cell injury start? The role of endothelin in
systemic sclerosis
David Abraham1 and Oliver Distler2
1Department of Medicine, Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital and University College, Rowland Hill Street,
London, NW3 2PF, UK
2Center of Experimental Rheumatology and Department of Rheumatology, University Hospital Zürich, Gloriastrasse, CH-8032 Zürich, Switzerland
Corresponding author: David Abraham, d.abraham@medsch.ucl.ac.uk
Published: 15 August 2007 Arthritis Research & Therapy 2007, 9(Suppl 2):S2 (doi:10.1186/ar2186)
This article is online at http://arthritis-research.com/content/9/S2/S2
© 2007 BioMed Central Ltd
AECA = anti-endothelial cell autoantibody; ECM = extracellular matrix; ET = endothelin; ETA/ETB = endothelin receptor subtype A/B; ICAM = inter-
cellular adhesion molecule; MMP = matrix metalloproteinase; NF-κB = nuclear factor-κB; PDGF = platelet-derived growth factor; SSc = systemic
sclerosis; TGF = transforming growth factor; TIMP = tissue inhibitor of metalloproteinase; TNF = tumour necrosis factor; vSMC = vascular smooth
muscle cell.
Page 2 of 8
(page number not for citation purposes)
Arthritis Research & Therapy    Vol 9 Suppl 2 Abraham and Distler
mechanical forces such as shear stress, as well as
inflammatory and angiogenic stimuli [1].
Triggers of endothelial cell injury and
dysfunction
Endothelial dysfunction is an important component of a
number of common human diseases, including those charac-
terized by inflammation and fibrosis (Figure 1). Our particular
interest is in the contribution of endothelial dysfunction to the
pathophysiology of inflammatory and fibrotic connective
tissue diseases and, in particular, SSc. Endothelial dys-
function is likely to result from endothelial cell injury triggered
via a number of different mechanisms, including the following
[2]: bacterial or viral infection; oxidative stress through
abnormal regulation of reactive oxygen species, hypoxia,
turbulent blood flow and shear stress; environmental irritants
such as tobacco; and hyperlipidaemia. These factors all lead
to the generation of an inflammatory process and endothelial
cell activation.
The endothelial response to injury can be divided into two
‘levels’ of response: an initial rapid response and a slower,
phenotypic response. The initial rapid response involves
(among other factors) changes in levels of nitric oxide,
prostaglandins, ET-1, von Willebrand factor and tissue
plasminogen activator. The slower response depends on
fundamental changes in cell surface characteristics, and
alterations in the underlying basement membrane and the
smooth muscle cells that surround the endothelium. These
changes are brought about by molecules that are particularly
potent growth factors involved in the deposition of ECM, and
activation and proliferation of the vSMCs, pericytes and other
mesenchymal cell types associated with the blood vessel
wall. This ultimately results in vessel remodelling, with
profound changes in cellular architecture [3].
Pericytes are associated with microvessels and capillaries
(about 30 µm diameter) and smooth muscle cells are
associated with intermediate (> 50 µm) and large (1 to 5 mm)
vessels and muscular arteries [4]. In terms of endothelial cells
and blood vessels, one must consider these as functional
units, which also involve both pericytes and vSMCs. In SSc
there are a number of important endothelium-derived media-
tors that have been shown to be important in the early
disease process. It is important to determine which of these
link vascular damage to the ensuing fibrogenic or pathogenic
tissue remodelling process and the characteristic signs and
symptoms of SSc.
Pathogenesis of systemic sclerosis
Over the past two decades considerable research effort has
been directed toward investigating and elucidating the
pathogenic processes of connective tissue diseases such as
SSc. Factors that determine susceptibility to these diseases,
and the precise nature of the initiating event, remain largely
unknown. However, they are likely to involve host genetics,
the impact of environmental cues, tissue injury, infection,
hypoxia and inability to control oxidative stress adequately [5]
(Figure 2).
Patients with SSc often exhibit early signs of vasculopathy,
with many experiencing Raynaud’s phenomenon, often for
many years before developing overt signs of skin fibrosis.
Consistent with this, morphological changes in capillaries are
detectable before or at disease onset, which can be used for
early diagnosis using nail-fold capillaroscopy. Changes in the
Figure 1
The myriad of potential consequences of endothelial dysfunction. Many human diseases, and in particular some of the most common diseases, are
characterized by abnormal changes that take place within the blood vessel and alter vascular responses and function. vSMC, vascular smooth
muscle cells.
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blood vessels of the SSc patient are frequently associated
with stimulation of both the innate and adaptive immune
responses, resulting in B-cell and T-cell activation and, in
many cases, autoantibody production. Inflammation is
believed to be a primary driver that leads to tissue
remodelling and gives rise to the characteristic features of
excess matrix production, caused by an imbalance in turnover
and increased deposition of various extracellular proteins [6].
The impact of this inflammation probably depends on the
organs involved, with evidence for a stronger association of
inflammation and fibrosis, for example, in the lungs, whereas
significant inflammatory infiltrates in the skin are limited to
perivascular areas in early-stage disease [7]. However, the
expression of profibrotic mediators is not limited to
inflammatory cells in the skin, and resident cells, such as
dermal fibroblasts, express increased levels of these
mediators in later stage disease [8].
These changes result in a sequence of pathological events
that includes impaired cell-cell communication between
epithelial cells and fibroblasts, and development of fibrotic
lesions that disrupt the normal tissue architecture and lead to
impaired expression of the correct molecular cues and
cellular mediators that maintain normal tissue structure and
function. Ultimately, these abnormalities lead to vascular and
interstitial fibrogenic processes. This so-called ‘replacement
fibrosis’ replaces normal tissue architecture and often leads
to organ compromise and failure [9].
Because early disease is initiated in the vasculature, and
many of the manifestations of SSc are vascular in nature
(capillary abnormalities, vessel occlusion and fibrosis, and
digital ulceration), identification of the components of the
pathway from the initial vascular insult to the downstream
fibrotic phenotype is critical. However, characterization of the
early vascular events is challenging in SSc, because patients
are usually available only in later stages of disease when the
disease is already established and because animal models
only incompletely reflect the human condition [10,11].
Regardless of the precise mechanisms that underlie the initial
vascular injury, it might be even more important to identify and
characterize the array of mediators driving the vascular
remodelling that leads to the vascular features typical of SSc.
Those mediators that are over-produced (beyond normal
levels of production) by endothelial cells of SSc patients
include growth factors, cytokines, and other mediators of
hyperplasia and hypertrophy. These include ET-1, connective
tissue growth factor and transforming growth factor (TGF)-β,
and matrix-modulating proteins such as matrix metalloprotein-
ases (MMPs) and natural tissue inhibitors of metalloproteinases
(TIMPs) [3,12]. They are also important regulators of the
activation and function of inflammatory mediators, including
tumour necrosis factor (TNF), interleukins and some chemo-
kines. These mediators in turn have a significant impact on
the progression of connective tissue diseases.
Anti-endothelial cell antibodies and oxidative
stress
Another important pathological feature of SSc, and one
which is probably highly relevant to the vasculopathy, is the
presence of specific anti-endothelial cell autoantibodies
(AECAs) [13,14]. These antibodies are a heterogeneous
Available online http://arthritis-research.com/content/9/S2/S2
Figure 2
Sequence of pathological events leading to the development of SSc. ECM, extracellular matrix; IL, interleukin; PDGF, platelet-derived growth
factor; SMC, smooth muscle cell; SSc, systemic sclerosis; TGF, transforming growth factor.
group of autoantibodies that specifically recognize endo-
thelial cell proteins and molecules present on the endothelial
cell surface. Studies of AECAs have shown that these
antibodies can also activate endothelial cells to express cell
adhesion molecules, thereby altering leucocyte attachment,
and can also lead to endothelial cell damage and apoptosis.
Several studies have also suggested that AECAs may play a
prominent role in disease progression. A recent study [15]
yielded the exciting finding that all SSc sera examined
expressed autoantibodies directed against platelet-derived
growth factor (PDGF) receptors. These autoantibodies were
found to stimulate PDGF receptor signalling, which led to the
generation of reactive oxygen species. This increase in
oxidative stress (a hallmark feature of SSc) strongly suggests
a pathogenic role for these autoantibodies in disease, and that
they are involved in autocrine and paracrine activities, and the
cascade of events that leads to enhanced ECM synthesis.
Thus, the identification of functional key players in the
processes that link vascular dysfunction to fibrogenesis will
assist in defining potential molecular targets for therapeutic
intervention. Along this line, processes that impact on both
the vascular and fibrotic pathogenic processes are of
particular interest. Although several molecular mediators are
involved in these processes, one of the key contributors is
ET-1. This article focuses on the biological function(s) of this
molecule, and the pivotal cell and molecular mechanism(s)
regulated by ET-1 in health and pathological activities in
connective tissue diseases.
The endothelin axis: role in the control of
vascular tone
The endothelins are a family of three vasoactive peptides
(ET-1, ET-2 and ET-3). The three 21-amino-acid endothelin
isoforms bind to two endothelin receptors (endothelin
receptor subtype A [ETA] and ETB), with equal affinities for
ETB but with a hierarchy of affinities for the ETA receptor. ET-1
has the highest affinity for ETA, followed by ET-2 and ET-3
[16]. The roles of the ETA and ETB receptors are becoming
less clearly distinguished as the literature expands. Indeed,
both have been implicated as mediators of the deleterious
effects of ET-1. The receptors exhibit a wide tissue distribution
and are expressed in kidney, liver, lung and skin; they are
known to be abnormally expressed in various diseases
characterized by defective vascular control. Abnormalities
observed in the endothelin system have been associated with
vasoconstriction, vasospasm and vascular hypertrophy.
Endothelin-1 and receptor interaction
ET-1 is the major and most studied endothelin isoform. ET-1
is produced by endothelial and mesenchymal cell types, such
as fibroblasts and smooth muscle cells, and acts in a
paracrine and autocrine manner. ET-1 production is
controlled by a number of soluble factors, including TGF-β,
which is a well recognized major profibrotic factor, and it
plays a major role in constriction and proliferation.
The ETA and ETB receptors have seven transmembrane
domains and are coupled to G proteins. ETA is expressed in
mesenchymal cells and ETB is expressed on endothelial cells.
ET-1 is produced as a pre-pro transcript that is translated into
a pre-pro polypeptide of 212 amino acids. The pre-pro
polypeptide is then processed by a series of converting
enzymes to proET-1 (or ‘big ET-1’), which is a large, relatively
inactive endothelin molecule that exhibits approximately 1%
of the activity of the fully functional 21-amino-acid peptide.
Big ET-1 is then converted by the membrane-bound enzyme
endothelin converting enzyme-1 into its functional, 21-amino-
acid form (Figure 3) [17-20]. It is then released as an active
form and binds to the specific endothelin receptors that are
expressed on a number of different cell types. ET-1 activity
can be inhibited with a number of classes of inhibitors that
act at different points along the endothelin cascade. Inhibitors
are available that selectively block endothelin converting
enzyme-1 to prevent production of the active peptide from big
ET-1; single or dual endothelin receptor antagonists block the
effects of ET-1 on target cells; cascade inhibitors disrupt the
intracellular signalling processes that are induced by ETA/ETB
binding; and inhibitors of transcription prevent transcriptional
activation and the downstream production of proteins that are
elevated by ET-1 and associated with the SSc phenotype.
Many of these inhibitors have been shown to interrupt the
effects of ET-1 effectively and have been the subject of a
plethora of basic science studies.
The widespread distribution of endothelin receptors on many
cell types suggests that they have important and wide-
ranging biological activities in vivo. In the context of our
understanding of the processes involved in SSc and other
connective tissue diseases, the primary ‘target’ cells for the
activity of ET-1 include smooth muscle cells, endothelial cells,
fibroblasts (and their differentiation to myofibroblasts, which
is the characteristic cell type of SSc and other connective
tissue diseases) and macrophages, in which activation by
ET-1 elicits a number of cell-type specific responses. In
smooth muscle cells ET-1 promotes vasoconstriction and
results in proliferation and elevated production of the key
profibrotic factors TGF-β and PDGF. In fibroblasts ET-1
increases ECM production and increases adhesion molecule
expression, thereby facilitating leucocyte-fibroblast inter-
actions. This is also observed in endothelial cells [21]. ETB
receptors are expressed by macrophages, and in these cells
ET-1 modulates inflammatory responses such as nuclear
factor-κB (NF-κB) activation, release of free radicals, and
increased levels of interleukin-8, monocyte chemoattractant
protein-1 [22] and TGF-β.
Multiple actions of endothelin
The important actions of ET-1 from the perspective of
connective tissue remodelling include induction of prolifer-
ation, chemotaxis of macrophages and smooth muscle cells,
activation of smooth muscle cells, and differentiation of
fibroblasts to myofibroblast phenotypes.
Arthritis Research & Therapy    Vol 9 Suppl 2 Abraham and Distler
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As introduced above, the biological activity of ET-1 with
respect to specific cell types can broadly be divided into two
types of functional response. The ‘early responses’ involve
cell signalling and calcium metabolism, are rapid and
transient, and are important with respect to cell contraction.
The slower, so-called ‘phenotypic responses’ culminate in the
characteristic remodelling phenotype of SSc. These latter
responses, which occur within hours and days rather than
minutes, involve transcriptional activation and stimulation of
modifying genes that control matrix (such as those encoding
MMPs and TIMPs), that potentiate the contractile machinery
(such as the actin and paxillin genes) and that alter tissue
architecture (for instance, genes encoding ECM proteins,
including collagen; Figure 4).
Endothelin-1 in the pathogenesis of systemic
sclerosis
Elevated levels of endothelin-1 are present in patients
with systemic sclerosis
There is now a wealth of evidence that ET-1 is expressed in
both early-stage and late-stage SSc. The protein has been
shown to be over-expressed in biological fluids and tissue
sections in patients with SSc, and increased expression of
ET-1 and increased receptor binding sites are found in
presclerotic and early diffuse skin lesions [23]. Elevated
levels of ET-1 have been observed in multiple organs that
are affected by SSc, notably blood vessels, lung, kidney and
skin [24].
Available online http://arthritis-research.com/content/9/S2/S2
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Figure 3
Overview of ET-1 biosynthesis and function. Endothelial cell stimulation
promotes the synthesis of pre-pro endothelin (ET)-1 polypeptides, the
activation of processes that result in production of ET-1, and local
release of mature ET-1. ET-1 interacts with specific endothelin receptors
(endothelin receptor subtype A [ETA] and ETB) expressed on the surface
of vascular smooth muscle cells and adventitial fibroblasts, and with ETB
receptors in endothelial cells. Recognition of ET-1 by these receptors
activates intracellular signalling pathways and cascades that result in
rapid alterations in cell activity and function, and initiates transcriptional
programmes. Several points along the pathways of production, release,
receptor ligation and signalling, as well as transcriptional activation, are
potential targets for intervention. aa, amino acids; ERA, endothelin
receptor antagonist; IL, interleukin; siRNA, small interfering RNA; SMC,
smooth muscle cell; TGF, transforming growth factor.
Figure 4
Dual action of ET-1 on mesenchymal cell types. Shown are key
activities of endothelin (ET)-1 on endothelial cells, vascular smooth
muscle cells (vSMCs) and fibroblasts. Rapid endothelin-mediated
responses include the modulation of calcium concentration and influx,
levels of nitric oxide (NO) and cGMP, and the associated contractile
response in order to regulate vascular tone. Slower more adaptive
responses include the activation of transcriptional programmes to
effect mesenchymal cell transition and differentiation, and extracellular
matrix (ECM) production resulting in tissue remodelling. DAG,
diacylglycerol; ETA/BR, endothelin receptor subtype A/B receptor; IP3,
inositol trisphosphate; MAPK, mitogen-activated protein kinase; PIP,
phosphatidylinositol phosphate; PKB, protein kinase B; PKC, protein
kinase C; PLC, phospholipase C.
Endothelin-1 is implicated in the pathological sequence
of events that is characteristic of systemic sclerosis
Within the context of tissue remodelling and fibrosis in SSc, it
is the vSMCs, fibroblasts and myofibroblasts that are the
cells of particular interest. Laboratory experiments have
focused on evaluating the characteristics of these cell types
and extrapolating the findings to what may occur in vivo, and
on determining how this information can be used effectively in
the clinical setting. Thus, we are interested in examining cell
contractility and migration, cell migration, inflammation, and
matrix deposition and remodelling.
ET-1 activates the surface expression of intercellular
adhesion molecule (ICAM)-1 on fibroblasts, and collagen
production by both dermal and pulmonary fibroblasts. It can
also stimulate fibroblasts to exhibit potent procontractile
properties and promote the formation of highly contractive
myofibroblasts [25,26]. In SSc it is important to note that the
MMP/TIMP cascade is dysregulated, with an increase in
many MMPs. Particularly intriguing is the elevation in MMP-2
(gelatinase A), which is capable of processing endothelin
precursors to active endothelin, thereby potentially
exacerbating the disease process. Classical and MMP-
activated endothelin can induce gene transcription and result
in the familiar cellular changes of fibrosis, matrix deposition
and tissue remodelling that are observed in SSc.
As well as matrix production and remodelling, SSc is
characterized by an early inflammatory response that involves
increased leucocyte infiltration to affected tissues and
elevated leucocyte-fibroblast interactions. Examining biopsies
from patients with early disease, Koch and coworkers [27]
found a number of cell adhesion molecules known to mediate
leucocyte interactions to be over-expressed. The nature of
these interactions has been addressed in a number of
studies, and the importance of the leucocyte function-
associated antigen-1/ICAM-1 pathway in T-cell/fibroblast
interaction has been noted [28]. In the laboratory, T cells
attach and bind more readily to SSc fibroblasts than to
control fibroblasts [29], and by using antibody blockade it is
possible to inhibit specifically the binding of these T cells to
SSc fibroblasts in vitro. Interestingly, ICAM-1 expression on
both normal and SSc fibroblasts is activated by ET-1. By
adding ET-1 and an antagonist, this increased attachment
could be inhibited. ET-1 therefore appears to increase ICAM-
1, which increases T-cell interaction with fibroblasts. It might
thus be an important factor in leucocyte recruitment into
extravascular tissues in the early inflammatory stages of SSc.
Further evidence for the role of ICAM-1 was recently reported
[30]. This study detailed the intracellular signalling pathways
that lead to the increased expression of ICAM-1 elicited by
ET-1 by using inhibitors of signalling pathways, transfections
with ICAM-1 promoter-reporter constructs, and electro-
phoretic mobility shift assays. The authors demonstrated that
the regulation of fibroblast ICAM-1 expression by ET-1 was
mediated by NF-κB. It was apparent that NF-κB is activated
by ET-1, which activates the ICAM-1 gene in a manner similar
to that with interleukin-1. ET-1 therefore can also play a
proinflammatory role, and is able to turn on ICAM-1 gene
expression and cause an increase in leucocyte-fibroblast
interaction. This upregulation of fibroblast ICAM-1 was found
to be potently inhibited by the dual endothelin receptor
antagonist bosentan and specific inhibitors of ET-1-
dependent signalling pathways [31].
Impact of endothelin receptor antagonists on the
pathophysiology of systemic sclerosis
Evidence for the involvement of ET-1 in the pathophysiology
of SSc also comes from receptor blockade studies. For
example, ET-1 has been shown to induce an expression
pattern in cultured lung fibroblasts similar to that in SSc
fibroblasts, and bosentan was shown to attenuate this
response and partially ‘normalize’ the scleroderma phenotype
[26]. These studies have been extended using Affymetrix
gene expression profiling of control fibroblasts and those
from SSc patients. These studies have shown that bosentan
reduces the differences observed between the gene
expression patterns in SSc and control lung fibroblasts. The
findings of experiments like these demonstrate that approxi-
mately one-third of genes that define the SSc signature are
modulated toward a more normal profile in the presence of
bosentan. However, it must be emphasized that the clinical
setting is extremely complex, and it is therefore difficult to
unravel fully the pathophysiological scenarios in the
laboratory using cell culture studies and animal models. There
is clearly significant crosstalk between different cell types in
the disease process as well as between different factors. The
temporal interaction(s) and links between these biological
processes are also important, as are the levels and
expression patterns of the critical mediators and responding
cell types. Data obtained thus far in the context of SSc
support the notion that ET-1 can play an important role in a
number of relevant pathological processes, including inflam-
mation, vasculopathy, tissue remodelling and fibrosis. This
places ET-1 as a key mediator in this disease.
Returning to the initial question of how endothelial cell injury
starts, the answer is that this remains elusive. There are some
excellent data from the UCD200 chicken scleroderma model
that suggest that endothelial cell apoptosis, promoted by
AECAs, is a key early event in endothelial injury [32], but the
human correlates have not been as convincing. However, is it
absolutely necessary to know the exact nature of the initiating
event(s), or is it equally important to understand the factors
that subsequently drive the disease process? One example
that supports the latter is the role played by TNF-α in
rheumatoid arthritis. Although the role, if any, that TNF-α
plays in the initiating events of rheumatoid arthritis is unclear,
it is very important in driving inflammation and subsequent
disease progression. This in turn defines TNF-α as an optimal
target for therapeutic intervention in rheumatoid arthritis.
Arthritis Research & Therapy    Vol 9 Suppl 2 Abraham and Distler
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Indeed, TNF-α inhibitors are now successfully used to treat
rheumatoid arthritis. Likewise, blocking critical mediators such
as ET-1, TGF-β and certain chemokines such as monocyte
chemoattractant protein-1 may likewise be effective in
preventing the progression of fibrotic diseases such as SSc.
Conclusion
Significant evidence suggests that ET-1 is important in a
number of aspects of fibrotic diseases such as SSc. In
inflammation, through induction of ICAM-1, ET-1 activates
adhesion molecule expression, which may be important in
regulating the inflammatory response that occurs in the early
stages of SSc. It is well accepted that endothelin plays a
major role in vasoconstriction, and it is an important mediator
in ECM remodelling and deposition. ET-1 can activate fibro-
blasts and other mesenchymal cells along the differentiation
pathway toward the myofibroblast, which is the principal
culprit in tissue remodelling, repair and ultimately fibrosis.
ET-1 activates adhesion molecule expression, which may be
important in regulating the inflammatory response. ET-1
receptor antagonists, such as bosentan, have been shown to
block early and late-stage manifestations of disease and may
thus help to prevent the progression of fibrotic diseases such
as SSc.
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